...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of oncology pharmacy practice: official publication of the International Society of Oncology Pharmacy Practitioners >Temozolomide plus radiotherapy for glioblastoma in a Canadian province: efficacy versus effectiveness and the impact of O6-methylguanine-DNA-methyltransferase promoter methylation.
【24h】

Temozolomide plus radiotherapy for glioblastoma in a Canadian province: efficacy versus effectiveness and the impact of O6-methylguanine-DNA-methyltransferase promoter methylation.

机译：替莫唑胺加放射疗法治疗加拿大胶质母细胞瘤：疗效与效果以及O6-甲基鸟嘌呤-DNA-甲基转移酶启动子甲基化的影响。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Radiotherapy with concomitant and adjuvant temozolomide has been the standard of care for newly diagnosed glioblastoma in adults since the pivotal trial by Roger Stupp and colleagues. The effectiveness of this regimen has not been evaluated in Canada. Additionally, the impact of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation on patient survival has not been confirmed. Hence, survival outcomes and MGMT predictive value were compared for the patients in Alberta versus the Stupp trial population.Retrospective chart review of 215 adult glioblastoma patients who started radiotherapy and temozolomide between January 2007 and December 2010 at the Cross Cancer Institute (Edmonton, Alberta) or the Tom Baker Cancer Centre (Calgary, Alberta).In the Alberta population, median overall survival was 14.3 months (vs. 14.6 months in trial, p?=?NS) and median progression-free survival was 5.8 months (vs. 6.9 months in trial, p?=?NS). However, unlike the trial, the Alberta MGMT subgroup analysis for overall survival was not statistically significant, despite a hazard ratio of 0.65 in favor of the methylated group. More Alberta patients received corticosteroids (p?
机译：自从Roger Stupp及其同事进行关键性试验以来，伴有替莫唑胺辅助治疗的放疗一直是成人新诊断成胶质细胞瘤的治疗标准。该方案的有效性尚未在加拿大进行评估。另外，尚未证实O6-甲基鸟嘌呤-DNA-甲基转移酶（MGMT）启动子甲基化对患者生存的影响。因此，我们比较了艾伯塔省和Stupp试验人群的生存结局和MGMT预测价值。回顾性图表回顾了2007年1月至2010年12月在Cross Cancer Institute（艾伯塔省埃德蒙顿）开始放疗和替莫唑胺的215名成年胶质母细胞瘤患者。或汤姆·贝克癌症中心（Tom Baker Cancer Center）（阿尔伯塔省卡尔加里市）。在阿尔伯塔省人群中，平均总生存期为14.3个月（试验中为14.6个月，p？=？NS），无进展生存期的中位数为5.8个月（对6.9）试用期为p？=？NS）。但是，与该试验不同，阿尔伯塔省MGMT亚组的总生存率没有统计学意义，尽管甲基化组的危险比为0.65。艾伯塔省接受皮质类固醇治疗的患者（p 0.0001）和进行全切除术（p = 0.0001）或行第二次手术后进行手术的患者（p = 0.01）少于Stupp人群，但其他方面的特征相似。艾伯塔省使患者能够实现与临床试验相似的总体和无进展生存期。需要进一步随访以确认MGMT分析的预测价值。在明确说明或开发出更好的治疗方法之前，无论MGMT甲基化状态如何，继续为患者提供这种治疗方案都是合理的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号